re-evaluating the use of iwg 2006 response criteria in mds
Published 2 years ago • 59 plays • Length 4:31Download video MP4
Download video MP3
Similar videos
-
2:48
validation of iwg 2023 criteria for response to treatment with hma in hr-mds
-
3:32
evaluating response criteria in myelodysplastic syndromes
-
1:30
the prognostic value of patient-reported outcomes in mds
-
3:10
the role of ngs in mds diagnosis
-
2:08
hematological response to frontline treatment in lr-mds is associated with better os
-
2:04
state-of-the-art treatment for hr-mds
-
4:48
managing and treating mds
-
1:11:40
sections a, i, j, o
-
6:17
classification and prognosis in mds
-
2:06
understanding the role of inflammation and the immunome in mds pathophysiology
-
1:41
an overview of the mds diagnosis pathway
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
2:52
long-term evaluation of luspatercept in esa-intolerant/refractory lr-mds: medalist follow-up study
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
2:35
methods of optimizing transplantation in mds
-
0:58
risk stratification in mds
-
1:17
the curative potential of allosct in the treatment of hr-mds
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve